Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
暂无分享,去创建一个
J. Foekens | A. Sieuwerts | M. Look | L. Dorssers | D. Meijer | T. van Agthoven | D. Meijer | A. M Sieuwerts | M. P Look | T. van Agthoven | J. A Foekens | L. C J Dorssers
[1] C. Sweep,et al. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer , 2003, Oncogene.
[2] M. Katoh,et al. WNT and FGF gene clusters (review). , 2002, International journal of oncology.
[3] M. Dowsett,et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] D. Hayes. Tamoxifen: Dr. Jekyll and Mr. Hyde? , 2004, Journal of the National Cancer Institute.
[5] R. Rubens,et al. Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. , 1978, European journal of cancer.
[6] J. Chang-Claude,et al. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[7] T. H. van der Kwast,et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.
[8] P. Fumoleau,et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis , 2004, British Journal of Cancer.
[9] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[10] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[11] L. Dorssers,et al. Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells , 2006, Molecular Cancer Research.
[12] Gillian E. Wu,et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. , 2002, The Journal of clinical investigation.
[13] H. Kurokawa,et al. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] H. Höfler,et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. , 2002, Cancer research.
[15] T. Dragani,et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. , 2005, Oncology reports.
[16] S. Shousha,et al. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer , 2001, The Journal of pathology.
[17] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[18] John W M Martens,et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. , 2005, Cancer research.
[19] R. Nicholson,et al. The Biology of Antihormone Failure in Breast Cancer , 2003, Breast Cancer Research and Treatment.
[20] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.
[21] Nobuyuki Itoh,et al. Fibroblast growth factors , 2001, Genome Biology.
[22] Mieke Timmermans,et al. How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study , 2005, Clinical Cancer Research.
[23] M. Konishi,et al. Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain. , 1998, Biochemical and biophysical research communications.
[24] F. Bertucci,et al. Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.
[25] Luc Y Dirix,et al. Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.
[26] B. Spencer‐Dene,et al. Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors , 2000, Breast Cancer Research.
[27] M. Smid,et al. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway , 2004, Breast Cancer Research.
[28] C. MacArthur,et al. Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.
[29] Shaun K Olsen,et al. Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.
[30] Maurice P H M Jansen,et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[32] T. Kishimoto,et al. Transforming activity of a newly cloned androgen-induced growth factor. , 1994, Oncogene.
[33] J. Foekens,et al. Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment. , 2000, Journal of the National Cancer Institute.
[34] C. MacArthur,et al. Genomic structure, mapping, activity and expression of fibroblast growth factor 17 , 1999, Mechanisms of Development.
[35] J. Foekens,et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.
[36] R. Coombes,et al. Increased expression of fibroblast growth factor 8 in human breast cancer , 1999, Oncogene.
[37] J. Foekens,et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Partanen,et al. Amplification of fgfr4 gene in human breast and gynecological cancers , 1993, International journal of cancer.
[39] V. P. Eswarakumar,et al. Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.
[40] J. Foekens,et al. Differential Effects of Fibroblast Growth Factors on Expression of Genes of the Plasminogen Activator and Insulin-like Growth Factor Systems by Human Breast Fibroblasts , 2002, Thrombosis and Haemostasis.
[41] J. Nährig,et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. Sotiriou,et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. , 2006, European journal of cancer.
[43] Yi Zhang,et al. Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Bianco,et al. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients , 2004, Breast Cancer Research and Treatment.